Ratio of FEV1/Slow Vital Capacity of < 0.7 Is Associated With Clinical, Functional, and Radiologic Features of Obstructive Lung Disease in Smokers With Preserved Lung Function

Published:February 01, 2021DOI:


      Mild expiratory flow limitation may not be recognized using traditional spirometric criteria based on the ratio of FEV1/FVC.

      Research Question

      Does slow vital capacity (SVC) instead of FVC increase the sensitivity of spirometry to identify patients with early or mild obstructive lung disease?

      Study Design and Methods

      We included 854 current and former smokers from the Subpopulations and Intermediate Outcome Measures in COPD Study cohort with a postbronchodilator FEV1/FVC ≥ 0.7 and FEV1 % predicted of ≥ 80% at enrollment. We compared baseline characteristics, chest CT scan features, exacerbations, and progression to COPD (postbronchodilator FEV1/FVC, < 0.7) during the follow-up period between 734 participants with postbronchodilator FEV1/SVC of ≥ 0.7 and 120 with postbronchodilator FEV1/SVC < 0.7 at the enrollment. We performed multivariate linear and logistic regression models and negative binomial and interval-censored proportion hazards regression models adjusted for demographics and smoking exposure to examine the association of FEV1/SVC < 0.7 with those characteristics and outcomes.


      Participants with FEV1/SVC < 0.7 were older and had lower FEV1 and more emphysema than those with FEV1/SVC ≥ 0.7. In adjusted analysis, individuals with postbronchodilator FEV1/SVC < 0.7 showed a greater percentage of emphysema by 0.45% (95% CI, 0.09%-0.82%), percentage of gas trapping by 2.52% (95% CI, 0.59%-4.44%), and percentage of functional small airways disease based on parametric response mapping by 2.78% (95% CI, 0.72%-4.83%) at baseline than those with FEV1/SVC ≥ 0.7. During a median follow-up time of 1,500 days, an FEV1/SVC < 0.7 was not associated with total exacerbations (incident rate ratio [IRR], 1.61; 95% CI, 0.97-2.64), but was associated with severe exacerbations (IRR, 2.60; 95% CI, 1.04-4.89). An FEV1/SVC < 0.7 was associated with progression to COPD during a 3-year follow-up even after adjustment for demographics and smoking exposure (hazard ratio, 3.93; 95% CI, 2.71-5.72). We found similar results when we examined the association of prebronchodilator FEV1/SVC < 0.7 or FEV1/SVC less than the lower limit of normal with chest CT scan features and progression to COPD.


      Low FEV1 to SVC in current and former smokers with normal spirometry results can identify individuals with CT scan features of COPD who are at risk for severe exacerbations and is associated with progression to COPD in the future.

      Trial Registry; No.: NCT01969344T4; URL:

      Graphical abstract

      Key Words


      CAT (COPD Assessment Test), LLN (lower limit of normal), mMRC (Modified Medical Research Council dyspnea), SVC (slow vital capacity), SPIROMICS (Subpopulations and Intermediate Outcome Measures in COPD Study), VC (vital capacity)
      To read this article in full you will need to make a payment


      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Singh D.
        • Agusti A.
        • Anzueto A.
        • et al.
        Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019.
        Eur Respir J. 2019; 53
        • Regan E.A.
        • Lynch D.A.
        • Curran-Everett D.
        • et al.
        Clinical and radiologic disease in smokers with normal spirometry.
        JAMA Intern Med. 2015; 175: 1539-1549
        • Woodruff P.G.
        • Barr R.G.
        • Bleecker E.
        • et al.
        Clinical significance of symptoms in smokers with preserved pulmonary function.
        N Engl J Med. 2016; 374: 1811-1821
        • Lowe K.E.
        • Regan E.A.
        • Anzueto A.
        • et al.
        COPDGene® 2019: redefining the diagnosis of chronic obstructive pulmonary disease.
        Chronic Obstr Pulm Dis. 2019; 6: 384-399
        • Chhabra S.K.
        Forced vital capacity, slow vital capacity, or inspiratory vital capacity: which is the best measure of vital capacity?.
        J Asthma. 1998; 35: 361-365
        • Pellegrino R.
        • Viegi G.
        • Brusasco V.
        • et al.
        Interpretative strategies for lung function tests.
        Eur Respir J. 2005; 26: 948-968
        • Saint-Pierre M.
        • Ladha J.
        • Berton D.C.
        • et al.
        Is the slow vital capacity clinically useful to uncover airflow limitation in subjects with preserved FEV1/FVC?.
        Chest. 2019; 156: 497-506
        • Couper D.
        • LaVange L.M.
        • Han M.
        • et al.
        Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS).
        Thorax. 2014; 69: 491-494
        • Hankinson J.L.
        • Odencrantz J.R.
        • Fedan K.B.
        Spirometric reference values from a sample of the general U.S. population.
        Am J Respir Crit Care Med. 1999; 159: 179-187
        • Bestall J.C.
        • Paul E.A.
        • Garrod R.
        • Garnham R.
        • Jones P.W.
        • Wedzicha J.A.
        Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease.
        Thorax. 1999; 54: 581-586
        • Jones P.W.
        • Harding G.
        • Berry P.
        • Wiklund I.
        • Chen W.H.
        • Kline Leidy N.
        Development and first validation of the COPD Assessment Test.
        Eur Respir J. 2009; 34: 648-654
        • Jones P.W.
        • Quirk F.H.
        • Baveystock C.M.
        The St George’s Respiratory Questionnaire.
        Respir Med. 1991; 85 (discussion 33-27): 25-31
        • Miller M.R.
        • Hankinson J.
        • Brusasco V.
        • et al.
        Standardisation of spirometry.
        Eur Respir J. 2005; 26: 319-338
        • Sieren J.P.
        • Newell Jr., J.D.
        • Barr R.G.
        • et al.
        SPIROMICS protocol for multicenter quantitative computed tomography to phenotype the lungs.
        Am J Respir Crit Care Med. 2016; 194: 794-806
        • Galban C.J.
        • Han M.K.
        • Boes J.L.
        • et al.
        Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression.
        Nat Med. 2012; 18: 1711-1715
        • Bhatt S.P.
        • Soler X.
        • Wang X.
        • et al.
        Association between functional small airway disease and FEV1 decline in chronic obstructive pulmonary disease.
        Am J Respir Crit Care Med. 2016; 194: 178-184
        • Kim V.
        • Crapo J.
        • Zhao H.
        • et al.
        Comparison between an alternative and the classic definition of chronic bronchitis in COPDGene.
        Ann Am Thorac Soc. 2015; 12: 332-339
        • Burns R.J.
        • Deschenes S.S.
        • Schmitz N.
        Associations between depressive symptoms and social support in adults with diabetes: comparing directionality hypotheses with a longitudinal cohort.
        Ann Behav Med. 2016; 50: 348-357
        • Brecthel L.
        • Gainey J.
        • Penwell A.
        • Nathaniel T.I.
        Predictors of thrombolysis in the telestroke and non telestroke settings for hypertensive acute ischemic stroke patients.
        BMC Neurol. 2018; 18: 215
        • Fortis S.
        • O’Shea A.M.J.
        • Beck Mae B.F.
        • et al.
        A simplified critical illness severity scoring system (CISSS): development and internal validation.
        J Crit Care. 2020; 61: 21-28
        • Zhang Z.
        Multiple imputation with multivariate imputation by chained equation (MICE) package.
        Ann Transl Med. 2016; 4: 30
        • Figueira Goncalves J.M.
        • Garcia Bello M.A.
        • Golpe R.
        • Alonso Jerez J.L.
        • Garcia-Talavera I.
        Impact of diabetes mellitus on the risk of severe exacerbation in patients with chronic obstructive pulmonary disease.
        Clin Respir J. 2020;
        • Han M.K.
        • Quibrera P.M.
        • Carretta E.E.
        • et al.
        Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.
        Lancet Respir Med. 2017; 5: 619-626
        • Fortis S.
        • Comellas A.
        • Make B.J.
        • et al.
        Combined forced expiratory volume in 1 second and forced vital capacity bronchodilator response, exacerbations, and mortality in chronic obstructive pulmonary disease.
        Ann Am Thorac Soc. 2019; 16: 826-835
      1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 report). Accessed October 1, 2020.

        • Fortis S.
        • Eberlein M.
        • Georgopoulos D.
        • Comellas A.P.
        Predictive value of prebronchodilator and postbronchodilator spirometry for COPD features and outcomes.
        BMJ Open Respir Res. 2017; 4e000213
        • Han M.K.
        • Kim M.G.
        • Mardon R.
        • et al.
        Spirometry utilization for COPD: how do we measure up?.
        Chest. 2007; 132: 403-409
        • Fortis S.
        Lost in interpretation: should the highest VC value be used to calculate the FEV1/VC?.
        Int J Chron Obstruct Pulmon Dis. 2016; 11: 2167-2170
        • Fortis S.
        • Corazalla E.O.
        • Wang Q.
        • Kim H.J.
        The difference between slow and forced vital capacity increases with increasing body mass index: a paradoxical difference in low and normal body mass indices.
        Respir Care. 2015; 60: 113-118
        • Huprikar N.A.
        • Skabelund A.J.
        • Bedsole V.G.
        • et al.
        Comparison of forced and slow vital capacity maneuvers in defining airway obstruction.
        Respir Care. 2019; 64: 786-792
        • Swanney M.P.
        • Ruppel G.
        • Enright P.L.
        • et al.
        Using the lower limit of normal for the FEV1/FVC reduces the misclassification of airway obstruction.
        Thorax. 2008; 63: 1046-1051
        • Wan E.S.
        • Fortis S.
        • Regan E.A.
        • et al.
        Longitudinal phenotypes and mortality in preserved ratio impaired spirometry in the COPDGene Study.
        Am J Respir Crit Care Med. 2018; 198: 1397-1405
        • Fortis S.
        • Comellas A.
        • Kim V.
        • et al.
        Low FVC/TLC in preserved ratio impaired spirometry (PRISm) is associated with features of and progression to obstructive lung disease.
        Sci Rep. 2020; 10: 5169
        • Schwartz A.
        • Arnold N.
        • Skinner B.
        • et al.
        Preserved ratio impaired spirometry in a spirometry database.
        Respir Care. 2021; 66: 58-65
        • Toren K.
        • Olin A.C.
        • Lindberg A.
        • et al.
        Vital capacity and COPD: the Swedish CArdioPulmonary bioImage Study (SCAPIS).
        Int J Chron Obstruct Pulmon Dis. 2016; 11: 927-933
        • Barros A.R.
        • Pires M.B.
        • Raposo N.M.
        Importance of slow vital capacity in the detection of airway obstruction.
        J Bras Pneumol. 2013; 39: 317-322
        • Pirozzi C.S.
        • Gu T.
        • Quibrera P.M.
        • et al.
        Heterogeneous burden of lung disease in smokers with borderline airflow obstruction.
        Respir Res. 2018; 19: 223
        • Hoesterey D.
        • Das N.
        • Janssens W.
        • et al.
        Spirometric indices of early airflow impairment in individuals at risk of developing COPD: spirometry beyond FEV1/FVC.
        Respir Med. 2019; 156: 58-68
        • Topalovic M.
        • Exadaktylos V.
        • Peeters A.
        • et al.
        Computer quantification of airway collapse on forced expiration to predict the presence of emphysema.
        Respir Res. 2013; 14: 131
        • Arjomandi M.
        • Zeng S.
        • Barjaktarevic I.
        • et al.
        Radiographic lung volumes predict progression to COPD in smokers with preserved spirometry in SPIROMICS.
        Eur Respir J. 2019; 54: 1802214
        • Zeng S.
        • Tham A.
        • Bos B.
        • Jin J.
        • Giang B.
        • Arjomandi M.
        Lung volume indices predict morbidity in smokers with preserved spirometry.
        Thorax. 2019; 74: 114-124
        • Guirguis-Blake J.M.
        • Senger C.A.
        • Webber E.M.
        • Mularski R.A.
        • Whitlock E.P.
        Screening for chronic obstructive pulmonary disease: evidence report and systematic review for the US Preventive Services Task Force.
        JAMA. 2016; 315: 1378-1393
        • Parkes G.
        • Greenhalgh T.
        • Griffin M.
        • Dent R.
        Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial.
        BMJ. 2008; 336: 598-600
        • Zhou Y.
        • Zhong N.S.
        • Li X.
        • et al.
        Tiotropium in early-stage chronic obstructive pulmonary disease.
        N Engl J Med. 2017; 377: 923-935
        • National Institutes of Health Clinical Center
        RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative (RETHINC).
        National Institutes of Health, Bethesda, MD2016
        • Bhatt S.P.
        • Balte P.P.
        • Schwartz J.E.
        • et al.
        Discriminative accuracy of FEV1:FVC thresholds for COPD-related hospitalization and mortality.
        JAMA. 2019; 321: 2438-2447